Table S1. Classification of CHD subtypes in our study

| Diagnosis | Number |
| :---: | :---: |
| Conotruncal $^{\text {Septal }^{\mathrm{a}}}$ | $139(33.3 \%)$ |
| RVOTO | $138(33.1 \%)$ |
| AVSD | $46(11.0 \%)$ |
| LVOTO | $22(5.3 \%)$ |
| APVR | $17(4.1 \%)$ |
| Complex $^{\mathrm{b}}$ | $12(2.9 \%)$ |
| Heterotaxy $^{\text {Others }^{\text {c }}}$ | $10(2.4 \%)$ |
| Total | $3(0.7 \%)$ |

AVSD: Atrioventricular septal defect; APVR: Anomalous pulmonary venous return; LVOTO: Left Ventricular outflow tract obstruction; RVOTO: Right ventricular outflow tract obstruction; PDA: Patent ductus arteriosus.
${ }^{\text {a }}$ Group "Septal" includes VSD, ASD (Except ASD I) etc.
${ }^{\text {b }}$ Group "Complex" includes single ventricle, L-TGA and multiple complex heart anomalies.
${ }^{\text {c }} 387$ out of 417 cases were classified into first eight groups according to the method introduced by Lorenzo et al. ${ }^{[1]}$. Whereas 30 cases can't be classified into the study mentioned above and are sorted into "Other" groups, which includes 17 cases of isolated PDA, 8 cases of aproctia with CHD, 2 cases of mitral insufficiency, 2 cases of aortopulmonary window and 1 mitral stenosis.

1. Botto, L.D., A.E. Lin, T. Riehle-Colarusso, S. Malik, A. Correa, and S. National Birth Defects Prevention, Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol, 2007. 79(10): p. 714-27.

## c.G711C (p.Q237H)



TGTTECCATT GTECTCACCTA Mutated Allele
T G T T G C CA T T C T G C T CA C C T A Reference Allele (Complementary strand)

## c.933_934 ins AA (p.T312K fs*55)



IGCIGTICTCACTCTAGCGAGC
TGCTGT T C T CAA ACTAA AGCGAMutated Allele
TGCTGT T CT CAC TAAAGCGAGCReference Allele
c.T811G (p.W271G)


T CAT GGAGGAGGGACTGATGGMutatedAllele T CA T G G A GGATGGAC TGATGGReference Allele
c.A1558C (p.S520R)


ACAT CGAGGTCGT GCTGATTTMutated Allele
ACAT CGAGGTAGTGCTGAT TTReference Allele

Table S2 Summary of mutations and clinical information of the carriers

| Nucleotide $^{\text {a }}$ | Amino Acid $^{\text {b }}$ | SIFT | POLYPhen-2 | Age | Gender | Diagnosis |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| c.G711C | p.Q237H | Tolerated | Benign | 1.3 | Male | PDA |
| c.T811G | p.W271G | Deleterious | Possibly damaging | 7.75 | Male | VSD, ASD, PDA |
| c.933_934 ins AA | p.T312K fs*55 | N/A | N/A | 3 | Female | ASD, PS |
| c.A1558C | p.S520R | Deleterious | Benign | 5.5 | Female | ASD, PS |
| c.C2186T | p.A729V | Tolerated | Benign | 11 | Female | Healthy control |

${ }^{\mathrm{a}}$ NM_020774.3; ${ }^{\text {b }}$ NP_065825.1.
ASD: Atrial septal defect; VSD: Ventricular septal defect; PDA: Patent ductus arteriosus; PS: Pulmonary Stenosis.

Table S3 Phenotypic statistics of zebrafish embryo injection

|  | Normal | Mild | Moderate | Severe | n | $\boldsymbol{p}$ (vs WT) |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Uninjected | 221 | 3 | 1 | 0 | 225 |  |  |
| Vector | 168 | 6 | 4 | 0 | 178 |  |  |
| Wild Type | 112 | 25 | 7 | 28 | 172 |  |  |
| p.Q237H | 101 | 21 | 13 | 9 | 144 | $*$ | Pearson |
| p.W271G | 193 | 33 | 16 | 3 | 245 | $* *$ | Pearson |
| p.T312K fs*55 | 182 | 12 | 7 | 6 | 207 | $* *$ | Fisher |
| p.S520R | 217 | 45 | 19 | 16 | 297 | $* *$ | Pearson |

*p<0.05; **p<0.01

